Comparison · NCT00305877-sae
Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation) vs Arm B (Bevacizumab, Gemcitabine, Capecitabine, Radiation): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation) vs Arm B (Bevacizumab, Gemcitabine, Capecitabine, Radiation): serious adverse events. Trial comparisons, record NCT00305877-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00305877-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.806 | 0.696 | 0.883 | wilson | |
| Risk in group 2 | 0.81 | 0.696 | 0.888 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00355 | -0.139 | 0.134 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.996 | 0.842 | 1.18 | log | |
| Odds ratio, group 1 over group 2 | 0.977 | 0.408 | 2.34 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation) than on Arm B (Bevacizumab, Gemcitabine, Capecitabine, Radiation) | 281 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation) | Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions). | 54 | 67 | EG000 |
| Group 2 | Arm B (Bevacizumab, Gemcitabine, Capecitabine, Radiation) | Patients receive bevacizumab IV over 60-90 minutes on day 1 every other week for 24 weeks. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in Arm A. | 51 | 63 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Assessed every 2 weeks while on treatment and for 30 days after the end of treatment
Source ClinicalTrials.gov
Trial
- Title
- Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
- NCT number
- NCT00305877
- Phases
- PHASE2
- Conditions
- Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- cetuximab, gemcitabine hydrochloride, capecitabine, radiation therapy, bevacizumab, laboratory biomarker analysis
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2013-11-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00305877?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00305877-sae